In this article, we will look at the 15 Best Cheap Stocks to Buy for 2026.Investors might feel like they have been overwhelmed by the news over the past year. But the stock market keeps reaching for new peaks every trading week. On January 28, the S&P 500 briefly crossed 7000 points for the first time, and the index has rebounded nearly 40% since its April 2025 lows. Just a day earlier, on January 27, the broad market index had notched its fifth record close, according to CNBC.The tech-heavy Nasdaq Composit ...

Group 1 - The importance of stock valuation for long-term returns is emphasized, indicating that even great companies can yield limited returns if purchased at a high premium [1] - A reliable method to assess a stock's value is through its forward price-to-earnings (P/E) ratio, which reflects expected earnings for the upcoming year, as opposed to trailing P/E [2] Group 2 - AbbVie has a forward P/E of just under 16, significantly lower than the S&P 500 average of 22, and a PEG ratio of around 0.40, indicating it is a strong buy [4][9] - AbbVie reported revenue of $44.5 billion for the first nine months of the year, an 8% increase year-over-year, with operating earnings of $10.5 billion, positioning it for high single-digit growth through the end of the decade [6] Group 3 - Micron Technology's shares have increased by approximately 250% in the past year, yet it maintains a forward P/E of 11 and a PEG ratio of 0.6, suggesting it remains undervalued [7] - The company is shifting focus from its consumer business to business-to-business operations due to high demand for memory and storage products, driven by tech investments in data centers and AI [8]

Core Insights - UnitedHealth Group Incorporated (UNH) has experienced a significant decline in stock value, falling 34.5% over the past year, which is worse than the industry's 28.4% decline and contrasts sharply with the S&P 500 Index's 16.9% growth [1][2] Financial Performance - The company has faced persistent cost pressures, rising utilization, regulatory scrutiny, and policy uncertainty, leading to multiple earnings misses and downward profit revisions [1][2] - The Zacks Consensus Estimate indicates a projected fourth-quarter earnings drop of 69.3% year-over-year to $2.09 per share, while revenue is expected to rise 12.7% to $113.64 billion [7] - For the full year 2025, earnings are estimated at $16.30 per share, reflecting a 41.1% decline, while revenues are projected to grow 11.9% to $448.03 billion [9] - Analysts expect a slight recovery in 2026, with earnings estimated at $17.60 per share, indicating nearly 8% growth, and revenues projected to rise 2.2% to $458.04 billion [10] Key Metrics - The medical care ratio (MCR) has increased significantly, from 82% in 2022 to nearly 90% in Q3 2025, which negatively impacts profitability [12] - Membership growth has slowed, with a decline of 3.9% in 2024, but is expected to rebound by 1.9% in 2025 [13] - Adjusted net margins have decreased sharply, projected at 3.3% for full-year 2025, with expectations of stabilization in 2026 [14] Market Position - UnitedHealth's forward P/E ratio stands at 19.07X, slightly below its five-year median but above the industry average of 15.84X, indicating mixed valuation perspectives [15] - The average analyst price target for UNH is $394.91, suggesting a potential upside of approximately 19%, although the wide target range reflects divided views on risk [17] Investor Sentiment - Recent insider buying by former CEO Stephen J. Hemsley and a $1.57 billion investment from Berkshire Hathaway indicate some confidence in the company's recovery potential [5][6] - However, the upcoming fourth-quarter earnings report is critical, as results falling short of expectations could lead to further selling pressure [11][19]

Core Insights - Not all cash-generating companies are successful; some fail to reinvest effectively, limiting growth potential [1] - StockStory aims to identify companies with genuine upside potential [1] Companies to Sell - **Elastic (ESTC)** - Trailing 12-Month Free Cash Flow Margin: 20.2% [2] - Current stock price is $88.32, with a forward price-to-sales ratio of 5.3x [4] - **Edgewell Personal Care (EPC)** - Trailing 12-Month Free Cash Flow Margin: 1.9% [5] - Current stock price is $18.53, with a forward P/E ratio of 6.4x [7] Company to Watch - **Laureate Education (LAUR)** - Trailing 12-Month Free Cash Flow Margin: 15.6% [8] - Estimated sales growth of 12.5% for the next 12 months, indicating a slowdown from previous trends [8] - Operating margin increased by 7.7 percentage points over the last year [8] - Free cash flow margin expected to decrease by 2.4 percentage points in the coming year [8] Performance Concerns - **Laureate Education (LAUR)** - Organic revenue has underperformed over the past two years, suggesting a need for acquisitions to stimulate growth [9] - Earnings per share declined by 2.6% annually over the last three years, with flat revenue indicating reduced profitability per sale [9] - Free cash flow margin decreased by 4.9 percentage points over the last year due to increased investments [9] Positive Aspects - **Laureate Education (LAUR)** - Strong operating margin of 23.5% over the past two years due to disciplined cost controls [11] - Free cash flow generation is superior to most peers, enabling exploration of new investment opportunities [11] - Increasing returns on capital as previous investments begin to yield results [11]

Core Viewpoint - The article discusses the volatility in the stock market, highlighting that while it presents opportunities, it also increases risks, making both significant gains and declines possible. The focus is on identifying one stock with potential for high returns and two stocks that are not recommended for investment. Group 1: Stocks to Sell - Albany (AIN) is a global textiles and materials processing company with a rolling one-year beta of 1.45, trading at $49.48 per share, which corresponds to a forward P/E of 16.1x [2][4] - Orion (ORN) provides construction services for marine infrastructure and industrial projects, has a rolling one-year beta of 2.34, and is priced at $10.09 per share, reflecting a forward P/E of 40.4x [5][7] Group 2: Stock to Watch - Community Bank (CBU) is a financial holding company with a rolling one-year beta of 1.09, offering various financial services. Its annual revenue growth over the last two years was 10.8%, indicating an increase in market share [8][11] - CBU's earnings per share grew by 5.5% annually over the last two years, significantly outperforming its peers [11] - The expected tangible book value per share growth of 20.2% suggests that CBU's capital strength will likely improve over the next 12 months [11]

Core Insights - Generating cash is crucial for businesses, but effective cash allocation is essential for investment potential [1] - StockStory identifies companies that utilize cash flow effectively, highlighting companies to avoid and better alternatives [1] Company Summaries J. M. Smucker (SJM) - Trailing 12-Month Free Cash Flow Margin is 7.7% [2] - Current stock price is $105.60, trading at 11.1x forward P/E [4] Mohawk Industries (MHK) - Trailing 12-Month Free Cash Flow Margin is 5.5% [5] - Current stock price is $107.56, implying a valuation ratio of 11x forward P/E [7] Champion Homes (SKY) - Trailing 12-Month Free Cash Flow Margin is 7.6% [8] - Estimated sales growth of 2.2% for the next 12 months indicates a slowdown in demand [9] - Organic revenue growth has underperformed benchmarks, suggesting a need for product and strategy improvements [10] - Operating margin has decreased by 27.1 percentage points due to rising day-to-day expenses relative to revenue [10] - Return on Invested Capital (ROIC) is 2.2%, indicating management challenges in identifying attractive investment opportunities [10]

Group 1 - The article discusses the author's extensive experience in the technology sector, highlighting a background of over 4 years and involvement with major companies like IBM [1] - The author has an MBA in finance and has been analyzing blue chip stocks for the past 6 years, which has provided valuable insights into the technology sector's dynamics [1] Group 2 - The article does not provide any specific investment recommendations or advice regarding the suitability of investments for particular investors [2][3] - There is a clear statement that past performance does not guarantee future results, emphasizing the uncertainty inherent in investment decisions [3]

Group 1 - The article discusses the author's extensive experience in the technology sector, highlighting a background of over 4 years with industry leaders like IBM and 6 years of covering blue chip stocks [1] - The author's MBA in finance has contributed to a deeper understanding of the technology sector, enabling better predictions of market trends and company performance [1] Group 2 - There are no disclosed positions in any mentioned companies, indicating an unbiased perspective in the analysis [2] - The article emphasizes that past performance does not guarantee future results, underscoring the importance of independent research for investors [3]